Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants

Activating mutations in KIT have been associated with gastrointestinal stromal tumors (GISTs). The tyrosine kinase inhibitor imatinib mesylate has revolutionized the treatment of GISTs. Unfortunately, primary or acquired resistance to imatinib does occur in GISTs and forms a major problem. Although...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Jie, Quan, Haitian, Xu, Yongping, Kong, Xiangqian, Jin, Lu, Lou, Liguang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317885/
https://www.ncbi.nlm.nih.gov/pubmed/24205792
http://dx.doi.org/10.1111/cas.12320

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317885/
https://www.ncbi.nlm.nih.gov/pubmed/24205792
http://dx.doi.org/10.1111/cas.12320

Ejemplares similares